PE20030350A1 - Solvatos de clorhidrato de lercanipidina y novedosas formas cristalinas de clorhidrato de lercanidipina que se obtienen a partir de dichos solvatos - Google Patents
Solvatos de clorhidrato de lercanipidina y novedosas formas cristalinas de clorhidrato de lercanidipina que se obtienen a partir de dichos solvatosInfo
- Publication number
- PE20030350A1 PE20030350A1 PE2002000716A PE2002000716A PE20030350A1 PE 20030350 A1 PE20030350 A1 PE 20030350A1 PE 2002000716 A PE2002000716 A PE 2002000716A PE 2002000716 A PE2002000716 A PE 2002000716A PE 20030350 A1 PE20030350 A1 PE 20030350A1
- Authority
- PE
- Peru
- Prior art keywords
- solvates
- hydrochloride
- lercanidipine hydrochloride
- refers
- lercanipidine
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/80—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D211/84—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen directly attached to ring carbon atoms
- C07D211/90—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Rheumatology (AREA)
- Hydrogenated Pyridines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
SE REFIERE A CLORHIDRATO DE LERCANIDIPINA [METIL 1,1,N-TRIMETIL-N-(3,3-DIFENILPROPIL)-2-AMINOETIL-1,4-DIHIDRO-2,6-DIMETIL-4-(3-NITROFENIL)PIRIDIN-3,5-DICARBOXILATO] CON SOLVENTES ORGANICOS QUE SE SELECCIONAN DE CLORURO DE METILENO, ACETONA, ANISOL, TETRAHIDROFURANO, METIL-TERBUTIL-ETER, ISOPROPANOL, ENTRE OTROS. LA FORMA CRISTALINA CON CLORURO DE METILENO PRESENTA DIFRACCION DE RAYOS X A LA LONGITUD DE ONDA KO CON UNA d(A) DESDE 2,04 A HASTA 6,6 A; UNA INTENSIDAD RELATIVA DE 29% A 100% Y UN ANGULO (2 0) DESDE 13,4 A 44,4. EL SOLVATO DE FORMA A PRESENTA ASIMISMO RESULTADOS DE DIFRACCION DE RAYO X A LA LONGITUD DE ONDA KO CON UNA d(A) DESDE 2,86 A HASTA 17,4 A, UNA INTENSIDAD RELATIVA DE 29% A 100% Y UN ANGULO (2 0) DESDE 5,1 A 31,3. EL CLORHIDRATO DE LERCANIDIPINA SE PRESENTE EN FORMA MICRONIZADA Y LA GRANULOMETRIAPROMEDIO DE DICHA FORMA ES DE D(50%) 2-8 um, D(90%) MENOR A 15 um. SE REFIERE TAMBIEN A COMPOSICIONES FARMACEUTICAS QUE CONTIENEN ENTRE 1,1 mg A 400mg DE UN AGENTE ACTIVO, DICHAS COMPOSICIONES COMPRENDEN CLORHIDRATO DE LERCANIDIPINA CRISTALINO DE LA FORMA III Y IV. SE REFIERE ADEMAS A UN PROCEDIMIENTO PARA LA PREPARACION
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IT2001MI001727A ITMI20011727A1 (it) | 2001-08-06 | 2001-08-06 | Solvati della lercanidipina cloridrato e nuove forme cristalline della lercanidipina cloridrato ottenute da essi |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20030350A1 true PE20030350A1 (es) | 2003-06-06 |
Family
ID=11448246
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2002000716A PE20030350A1 (es) | 2001-08-06 | 2002-08-06 | Solvatos de clorhidrato de lercanipidina y novedosas formas cristalinas de clorhidrato de lercanidipina que se obtienen a partir de dichos solvatos |
Country Status (21)
| Country | Link |
|---|---|
| EP (1) | EP1423367B1 (es) |
| JP (1) | JP2005502648A (es) |
| KR (1) | KR100912664B1 (es) |
| CN (1) | CN100494175C (es) |
| AR (1) | AR037230A1 (es) |
| AT (1) | ATE294162T1 (es) |
| AU (1) | AU2002331390B2 (es) |
| BR (1) | BR0211738A (es) |
| DE (1) | DE60203919D1 (es) |
| EA (1) | EA200400279A1 (es) |
| ES (1) | ES2209684T1 (es) |
| HR (1) | HRP20040157A2 (es) |
| HU (1) | HUP0401161A3 (es) |
| IL (2) | IL153916A0 (es) |
| IT (1) | ITMI20011727A1 (es) |
| MX (1) | MXPA04001073A (es) |
| NO (1) | NO20040479L (es) |
| PE (1) | PE20030350A1 (es) |
| PL (1) | PL369449A1 (es) |
| UY (1) | UY27409A1 (es) |
| WO (1) | WO2003014085A1 (es) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100651212B1 (ko) | 2004-10-27 | 2006-12-01 | 제일약품주식회사 | 무정형 레르카니디핀의 제조방법 |
| AR052918A1 (es) | 2005-02-25 | 2007-04-11 | Recordati Ireland Ltd | Clorhidrato de lercanidipina amorfo |
| US8097729B2 (en) | 2005-09-16 | 2012-01-17 | Glenmark Generics Ltd. | Polymorphic form of lercanidipine hydrochloride and process for the preparation thereof |
| WO2008107797A2 (en) * | 2007-03-05 | 2008-09-12 | Actavis Group Ptc Ehf | Lercanidipine hydrochloride polymorphs and an improved process for preparation of 1,1,n-trimethyl-n-(3,3-diphenylpropyl)-2-aminoethyl acetoacetate |
| WO2008136392A1 (ja) * | 2007-04-27 | 2008-11-13 | Ajinomoto Co., Inc. | 経口投与用製剤 |
| WO2011161223A2 (en) | 2010-06-23 | 2011-12-29 | Krka, Tovarna Zdravil, D.D., Novo Mesto | Pharmaceutical oral dosage forms comprising lercanidipine and enalapril and their pharmaceutically acceptable salts |
| SI2654729T1 (sl) | 2010-12-24 | 2016-08-31 | Krka, D.D., Novo Mesto | Homogene farmacevtske oralne dozirne oblike, ki obsegajo lerkanidipin in enalapril ali njune farmacevtsko sprejemljive soli skupaj z organsko kislino |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8403866D0 (en) | 1984-02-14 | 1984-03-21 | Recordati Chem Pharm | Diphenylalkylaminoalkyl esters |
| US5767136A (en) * | 1995-05-12 | 1998-06-16 | Recordati, S.A. Chemical And Pharmaceutical Company | 1,4-Dihydropyridines useful for prevention or reduction of atherosclerotic lesions on arterial walls |
-
2001
- 2001-08-06 IT IT2001MI001727A patent/ITMI20011727A1/it unknown
-
2002
- 2002-08-02 AR ARP020102957A patent/AR037230A1/es not_active Application Discontinuation
- 2002-08-05 PL PL02369449A patent/PL369449A1/xx unknown
- 2002-08-05 CN CNB028155114A patent/CN100494175C/zh not_active Expired - Fee Related
- 2002-08-05 JP JP2003519035A patent/JP2005502648A/ja active Pending
- 2002-08-05 HU HU0401161A patent/HUP0401161A3/hu unknown
- 2002-08-05 KR KR1020047001791A patent/KR100912664B1/ko not_active IP Right Cessation
- 2002-08-05 MX MXPA04001073A patent/MXPA04001073A/es not_active Application Discontinuation
- 2002-08-05 AU AU2002331390A patent/AU2002331390B2/en not_active Ceased
- 2002-08-05 IL IL15391602A patent/IL153916A0/xx unknown
- 2002-08-05 AT AT02767318T patent/ATE294162T1/de not_active IP Right Cessation
- 2002-08-05 DE DE60203919T patent/DE60203919D1/de not_active Expired - Lifetime
- 2002-08-05 WO PCT/EP2002/008700 patent/WO2003014085A1/en active IP Right Grant
- 2002-08-05 ES ES02767318T patent/ES2209684T1/es active Pending
- 2002-08-05 BR BR0211738-0A patent/BR0211738A/pt not_active IP Right Cessation
- 2002-08-05 EP EP02767318A patent/EP1423367B1/en not_active Expired - Lifetime
- 2002-08-05 EA EA200400279A patent/EA200400279A1/ru unknown
- 2002-08-06 PE PE2002000716A patent/PE20030350A1/es not_active Application Discontinuation
- 2002-08-06 UY UY27409A patent/UY27409A1/es not_active Application Discontinuation
-
2003
- 2003-01-13 IL IL153916A patent/IL153916A/en unknown
-
2004
- 2004-02-03 NO NO20040479A patent/NO20040479L/no not_active Application Discontinuation
- 2004-02-18 HR HR20040157A patent/HRP20040157A2/hr not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| KR100912664B1 (ko) | 2009-08-17 |
| PL369449A1 (en) | 2005-04-18 |
| DE60203919D1 (de) | 2005-06-02 |
| AR037230A1 (es) | 2004-11-03 |
| NO20040479L (no) | 2004-02-03 |
| EP1423367B1 (en) | 2005-04-27 |
| ATE294162T1 (de) | 2005-05-15 |
| WO2003014085A1 (en) | 2003-02-20 |
| ITMI20011727A0 (it) | 2001-08-06 |
| MXPA04001073A (es) | 2005-02-17 |
| AU2002331390B2 (en) | 2008-06-05 |
| IL153916A0 (en) | 2003-07-31 |
| JP2005502648A (ja) | 2005-01-27 |
| HUP0401161A2 (hu) | 2004-09-28 |
| ITMI20011727A1 (it) | 2003-02-06 |
| BR0211738A (pt) | 2004-09-28 |
| EA200400279A1 (ru) | 2004-06-24 |
| ES2209684T1 (es) | 2004-07-01 |
| HUP0401161A3 (en) | 2009-04-28 |
| CN1538958A (zh) | 2004-10-20 |
| CN100494175C (zh) | 2009-06-03 |
| KR20040030932A (ko) | 2004-04-09 |
| EP1423367A1 (en) | 2004-06-02 |
| IL153916A (en) | 2008-07-08 |
| HRP20040157A2 (en) | 2004-08-31 |
| UY27409A1 (es) | 2003-03-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2218922C2 (ru) | Соединения, имеющие в своей структуре фрагмент производного глюкуроновой кислоты и фрагмент производного глюкозамина, способы получения этих соединений и применение этих соединений | |
| CA2385890A1 (en) | Controlled release compositions comprising nimesulide | |
| NO20085077L (no) | Nye forbindelser | |
| KR970706837A (ko) | 약학 조성물 (pharmaceutical compositions) | |
| AR033859A1 (es) | Inhibidores de la metaloproteinasa de la matriz | |
| ATE383850T1 (de) | Pulver enthaltend neuartige oligosaccharidgemische und verfahren zu deren herstellung | |
| AU5669398A (en) | Novel cyclosporin derivatives, method of preparation and pharmaceutical compositions containing them | |
| HUP0400070A2 (hu) | 17alfa-helyzetben ciklusos észtercsoportot tartalmazó androsztán-17béta-karbotiosav-észter-származékok mint gyulladásgátló szerek, eljárás a vegyületek előállítására és ezeket tartalmazó gyógyszerkészítmények | |
| IL179718A0 (en) | Pharmaceutical composition containing irbesartan | |
| SG147450A1 (en) | Sustained release pharmaceutical compositions comprising aplindore and derivatives thereof | |
| BRPI0518781A2 (pt) | formulaÇço farmacÊutica, processo para preparar uma formulaÇço farmacÊutica, e, uso de um composto | |
| AP1776A (en) | Reconstitutable parenteral composition containing a cox-2 inhibitor. | |
| PE20030350A1 (es) | Solvatos de clorhidrato de lercanipidina y novedosas formas cristalinas de clorhidrato de lercanidipina que se obtienen a partir de dichos solvatos | |
| HUP0002683A2 (hu) | Terápiás anyagok sejtekhez való eljuttatásának fokozására szolgáló készítmények és módszerek | |
| EP0992509A3 (en) | Novel macrolide derivatives | |
| CY1105168T1 (el) | Διφασικη συνθεση με τραμαδολη | |
| KR910016332A (ko) | 수난용성 약제를 함유하는 약학 조성물 | |
| AR009651A1 (es) | Composicion solubilizante/estabilizante anhidra, emulsionable o microemulsionable en agua, para la solubilizacion de los derivados hidrofobosde n-sulfonil indolina, composicion farmaceutica microemulsionable o emulsionable en medio acuoso, y capsulas farmaceuticas, particularmente blandas | |
| NO20055016L (no) | Farmasoytisk sammensetning som fast doseringsform og fremgangsmate for fremstilling derav | |
| HUP0300557A2 (hu) | N-dezacetiltiokolkicin-származékok és ilyen vegyületeket tartalmazó gyógyászati készítmények | |
| EP1300160A4 (en) | METHOD FOR STABILIZING A PREPARATION | |
| PT97164A (pt) | Processo para a estabilizacao de uma preparacao que contenham o composto 4-etil-2-hidroxi-imino-5-nitro-3-hexenamida e de composicoes farmaceuticas que o contenham | |
| EP2066301B1 (en) | Injectable pharmaceutical nimesulide solutions | |
| DK0946585T3 (da) | Steroidforbindelser substitueret i stilling 11, fremgangsmåde til deres fremstilling, deres anvendelse som lægemidler og farmaceutiske præparater med indhold deraf | |
| CS235524B2 (en) | Method of levonantradole derivatives solubilization |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FD | Application declared void or lapsed |